

Pavel Mějek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7155491/publications.pdf>

Version: 2024-02-01

33
papers

451
citations

840776

11
h-index

752698

20
g-index

33
all docs

33
docs citations

33
times ranked

745
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement Activation Dramatically Accelerates Blood Plasma Fouling On Antifouling Poly(2-hydroxyethyl methacrylate) Brush Surfaces. <i>Macromolecular Bioscience</i> , 2022, 22, e2100460.	4.1	4
2	Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome. <i>PLoS ONE</i> , 2022, 17, e0262484.	2.5	5
3	Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome. <i>Cancer Biomarkers</i> , 2022, , 1-8.	1.7	0
4	Extension of the Human Fibrinogen Database with Detailed Clinical Informationâ€”The Î±C-Connector Segment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 132.	4.1	3
5	Endothelialization of an ePTFE vessel prosthesis modified with an antithrombogenic fibrin/heparin coating enriched with bound growth factors. <i>RSC Advances</i> , 2021, 11, 5903-5913.	3.6	11
6	Impact of posttranslational modifications on atomistic structure of fibrinogen. <i>PLoS ONE</i> , 2020, 15, e0227543.	2.5	16
7	Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. <i>Free Radical Biology and Medicine</i> , 2017, 108, 1-7.	2.9	12
8	Alpha-2-HS-glycoprotein plasma level decrease correlates with age in patients with myelodysplastic syndromes. <i>Cancer Biomarkers</i> , 2017, 20, 637-639.	1.7	4
9	Posttranslational Modifications of Red Blood Cell Ghost Proteins as â€œSignaturesâ€”for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients. <i>Turkish Journal of Haematology</i> , 2017, 34, 111-113.	0.5	1
10	Total removal of intact blood plasma proteins deposited on surface-grafted polymer brushes. <i>Analytical Methods</i> , 2016, 8, 6415-6419.	2.7	5
11	Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	5
12	Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome. <i>BioMed Research International</i> , 2015, 2015, 1-17.	1.9	3
13	N-Glycosylation of apolipoprotein A1 in cardiovascular diseases. <i>Translational Research</i> , 2015, 165, 360-362.	5.0	4
14	Protein Carbonylation in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 5232-5232.	1.4	1
15	A novel natural mutation A1Phe98Ile in the fibrinogen coiled-coil affects fibrinogen function. <i>Thrombosis and Haemostasis</i> , 2014, 111, 79-87.	3.4	7
16	Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2. <i>Disease Markers</i> , 2014, 2014, 1-8.	1.3	16
17	Surface plasmon resonance: advances of label-free approaches in the analysis of biological samples. <i>Bioanalysis</i> , 2014, 6, 3325-3336.	1.5	17
18	Abnormal Fibrinogen Z1Än (γThr21Ile) with Missense Mutation Causing Hypofibrinogenemia. <i>Acta Haematologica</i> , 2014, 132, 140-143.	1.4	2

#	ARTICLE	IF	CITATIONS
19	The effect of the biological variability of samples on Coomassie blue dye based fast staining for SDS-PAGE in nonfixed gels. Electrophoresis, 2014, 35, 3008-3011.	2.4	3
20	Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science, 2013, 11, 14.	1.7	15
21	Staining of proteins for 2D SDS-PAGE using Coomassie Blue—speed versus sensitivity?. Electrophoresis, 2013, 34, 1972-1975.	2.4	5
22	Novel homozygous fibrinogen A α chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy. Thrombosis Research, 2013, 132, 490-492.	1.7	4
23	Complete Identification of Proteins Responsible for Human Blood Plasma Fouling on Poly(ethylene) Terephthalate. Journal of Proteomics, 2013, 16, 107-121.	3.5	121
24	Improved Coomassie Blue Dye-Based Fast Staining Protocol for Proteins Separated by SDS-PAGE. PLoS ONE, 2013, 8, e81696.	2.5	8
25	Proteomic analysis of plasma samples from acute coronary syndrome patients—The pilot study. International Journal of Cardiology, 2012, 157, 126-128.	1.7	2
26	Simplified platelet sample preparation for SDS-PAGE-based proteomic studies. Proteomics - Clinical Applications, 2012, 6, 374-381.	1.6	5
27	Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Science, 2012, 10, 31.	1.7	12
28	Proteomic analysis of the plasma samples of patients with stable angina pectoris. Cor Et Vasa, 2012, 54, e22-e26.	0.1	1
29	Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Science, 2011, 9, 64.	1.7	18
30	Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. Journal of Translational Medicine, 2011, 9, 84.	4.4	30
31	Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Science, 2010, 8, 56.	1.7	44
32	Antioxidants change platelet responses to various stimulating events. Free Radical Biology and Medicine, 2009, 47, 1707-1714.	2.9	33
33	Acquired Dysfibrinogenemia Secondary to Multiple Myeloma. Acta Haematologica, 2008, 120, 75-81.	1.4	34